Baker Bros. Capital (GP), LLC

CIK 1244390 · last filed 2012-01-04

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$36.03M

Companies

8

Total Filings

18

Lifetime Open-Market Net

-$726.6K

Filer Profile

Reported Address

667 MADISON AVE
21ST FLOOR
NEW YORK, NY 10065

Phone

(212) 339-5600

State of Incorporation

Formerly Known As

BAKER BROS CAPITAL GP LLC (2003–2005)

Related Filers

JULIAN BAKER — 170 joint filings, latest 2012-01-31

FELIX BAKER — 155 joint filings, latest 2012-01-31

INCYTE CORP — 26 joint filings, latest 2011-07-05

14159 capital (GP), LLC — same reported address

Baker / Tisch Capital (GP), LLC — same reported address

Baker Biotech Capital (GP), LLC — same reported address

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Seagen Inc. (SGEN) Delisted	Director	539,130	$228.74	$123.32M	$119.4K	3	2012-01-04
BCRX	10%+ Owner	62,407	$9.16	$571.6K	$0	1	2011-07-05
GENOMIC HEALTH INC (GHDX) Delisted	Director	194,415	—	—	$9.4K	2	2011-06-09
VIROPHARMA INC (VPHM) Delisted	10%+ Owner	105,694	—	—	-$428.5K	2	2009-05-20
INCY	Director	284,025	$124.86	$35.46M	$46.2K	4	2008-12-22
Aceragen, Inc. (IDRA) Delisted	10%+ Owner	3,098	$7.22	$22.4K	-$75.2K	1	2008-07-16
Ardea Biosciences, Inc./DE (RDEA) Delisted	10%+ Owner	163,256	—	—	$81.8K	2	2008-05-30
Aceragen, Inc. (IDP) Delisted	10%+ Owner	95,563	—	—	-$479.6K	2	2007-12-07

Recent Filings · Page 2 of 2

18 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2008-01-31	INCY	Buy (P)	—	$0	EDGAR
2007-12-21	Ardea Biosciences, Inc./DE (RDEA) Delisted	Buy (P)	+6,177	$81.8K	EDGAR
2007-12-19	INCY	Buy (P)	+1,296	$13.7K	EDGAR
2007-12-12	INCY	Buy (P)	+2,366	$23.6K	EDGAR
2007-12-07	Aceragen, Inc. (IDP) Delisted	Sell (S)	−13,131	-$161.7K	EDGAR
2007-10-31	Aceragen, Inc. (IDP) Delisted	Sell (S)	−26,259	-$317.9K	EDGAR
2007-05-21	GENOMIC HEALTH INC (GHDX) Delisted	Other (J)	+5,409	$83.8K	EDGAR
2007-04-17	VIROPHARMA INC (VPHM) Delisted	Sell (S)	−28,029	-$430.5K	EDGAR

Showing 11–18 of 18

Prev Page 2 of 2

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.